Jennifer Good Sells Shares of Rhythm Pharmaceuticals

Jennifer Good, an insider at Rhythm Pharmaceuticals, Inc. (NasdaqGM:RYTM), sold 4,712 shares of the company on June 23, 2026. The details of the transaction, including the price per share and total value, were not disclosed.

Other Institutional Activity in Rhythm Pharmaceuticals

RA Capital Management, L.P. maintained its position in Rhythm Pharmaceuticals with 6,666,837 shares valued at approximately $579.8 million. BlackRock, Inc. reduced its holdings by 60,183 shares, leaving it with 6,237,151 shares worth about $542.4 million, a 1.0% decrease. Baker Bros. Advisors LP also held steady with 5,604,483 shares valued at around $487.4 million. Primecap Management Co/CA/ trimmed its stake by 61,160 shares, ending with 3,417,509 shares valued at roughly $297.2 million, a 1.8% decrease. Vanguard Portfolio Management LLC opened a new position with 3,040,718 shares valued at approximately $264.5 million.

Rhythm Pharmaceuticals, Inc. Stock Up 0.4%

Shares of NasdaqGM:RYTM traded near $107.55 on Friday. Rhythm Pharmaceuticals has a market cap of approximately $6.95 billion. The stock has a beta of 1.923, indicating higher volatility compared to the market. Its 52-week range is between $60.80 and $122.20, with a 50-day moving average of $88.36 and a 200-day moving average of $97.77. The company's current ratio stands at 4.168, and it has a quick ratio of 3.632 with a debt-to-equity ratio of 47.264.

Recent Earnings

Rhythm Pharmaceuticals reported revenue of $217.2 million, showing a growth rate of 83.8%. However, the company is not yet profitable, with a net margin of -93.33% and a return on equity of -101.16%. The next earnings report is expected on August 4, 2026.

Analysts Set New Price Targets

On June 16, 2026, Canaccord Genuity maintained its buy rating on Rhythm Pharmaceuticals with a price target of $151. Wells Fargo also maintained a buy rating, setting a target of $155 on June 15. The consensus among analysts is a strong buy, with a mean price target of $139.47 based on 15 analyst opinions.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company based in Boston, Massachusetts. It focuses on developing treatments for rare neuroendocrine diseases. Its lead product, IMCIVREE (setmelanotide), targets multiple rare genetic conditions related to obesity. The company is also working on other treatments in various stages of clinical trials. Founded in 2008, Rhythm Pharmaceuticals is led by CEO Dr. David P. Meeker and employs 414 people.

Bottom Line

Jennifer Good's sale of shares in Rhythm Pharmaceuticals is a notable insider transaction, though it doesn't necessarily indicate her outlook on the company's future. Rhythm Pharmaceuticals continues to develop treatments for rare conditions, attracting attention from institutional investors. Analysts maintain a strong buy consensus, reflecting optimism about the company's prospects despite its current lack of profitability.